STARS Webinar - Finding the Right Dose: Using Patient-Reported Data in Early Phase Clinical Trials-Finding the Right Dose: Using Patient-Reported Data in Early Phase Clinical Trials

Video Transcription

Video Summary

In this webinar, the speakers discussed the importance of patient-reported data in determining the right dose for patients in early phase clinical trials. They highlighted the need for a shift away from the traditional maximum tolerated dose paradigm and towards a more personalized approach based on patient experiences and preferences. The Patient-Centered Dosing Initiative (PCDI) conducted surveys of patients and oncologists to gather data on treatment-related side effects and found that most patients experienced side effects and felt better on a lower dose. The speakers emphasized the importance of patient advocacy in promoting discussions between patients and physicians about flexible dosing options based on individual characteristics. They also discussed ongoing efforts by regulatory agencies such as the FDA to reform dose optimization and provide guidance to drug developers. The speakers shared their own experiences as patient advocates and emphasized the value of patient-reported outcomes in improving treatment outcomes and quality of life for patients. They encouraged attendees to get involved in advocacy work, such as joining institutional review boards, participating in expert panels, and reviewing trial protocols and informed consent forms. Overall, the webinar highlighted the importance of patient-reported data and patient advocacy in finding the right dose for patients in early phase clinical trials. And promoting personalized and effective treatments.

Asset Subtitle

(English)

Meta Tag

Concept 33 Design

Concept Dose-Limiting Toxicity

Concept Maximum Tolerated Dose

Concept Dose Optimization

Concept Recommended phase 2 dose

Keywords

patient-reported data

dose determination

early phase clinical trials

maximum tolerated dose

patient experiences

flexible dosing options

patient advocacy

dose optimization

patient-reported outcomes

personalized treatments

33 Design

Dose-Limiting Toxicity

Maximum Tolerated Dose

Dose Optimization

Recommended phase 2 dose